MARLBOROUGH, Mass. / Apr 22, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX), a company that develops industry-leading technologies that detect, diagnose and treat life-changing health conditions that affect women, today released its annual sustainability report with an emphasis on expanded environmental commitments and efforts to advance access and equity in women’s health.
For almost four decades, Hologic has pushed the limits of what’s possible to improve women’s health, and in 2024 its technologies impacted more than 193 million lives worldwide.1 As a science-based company, it has a long-standing approach to operate sustainably and responsibly.
“We firmly believe that our success as a company is fundamentally tied to our ability and commitment to help millions of women worldwide live healthier lives,” said Hologic Chairman, President and CEO Stephen P. MacMillan. “This is our reason for being. For us, women’s health is more than a business; it is our purpose: to enable healthier lives everywhere, every day.”
The newly launched report covers four areas of focus reflecting the issues that directly impact Hologic’s stakeholders, communities and women around the world. Below are highlights from each area in 2024:
Advancing Women’s Access and Equity in Healthcare
Protecting the Environment
Supporting Our People and Communities
Operating With Integrity
To read the full sustainability report, please visit www.hologic.com/sustainability.
About Hologic, Inc.
Hologic, Inc. is a global leader in women’s health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com and connect with us on LinkedIn, Facebook, X, Instagram and YouTube.
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
Hologic, The Science of Sure, Genius and Genius AI are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
References and Notes |
1. Lives impacted include assays, mammograms, surgical treatments and other Hologic procedures. |
2. FDA clearance followed CE Mark. |
3. Available in Europe, Australia, New Zealand and the United States. |
4. Scope 1: direct emissions; Scope 2: emissions from purchased energy; Scope 3: indirect emissions in the value chain. |
Last Trade: | US$58.20 |
Daily Change: | -0.16 -0.27 |
Daily Volume: | 2,713,263 |
Market Cap: | US$13.140B |
April 24, 2025 February 25, 2025 February 18, 2025 February 05, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load